Aspire Biopharma
ASBP
14 hedge funds and large institutions have $17M invested in Aspire Biopharma in 2023 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 51 closing their positions.
0.07% less ownership
Funds ownership: 0.07% → 0% (-0.07%)
75% less funds holding
Funds holding: 57 → 14 (-43)
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
84% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 51
94% less capital invested
Capital invested by funds: $268M → $17M (-$251M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Arena Investors
Purchase,
New York
|
+$1.57M |
| 2 |
ETH
Exos TFP Holdings
New York
|
+$1.57M |
| 3 |
PSAMP
P. Schoenfeld Asset Management (PSAM)
New York
|
+$1.57M |
| 4 |
SIM
Sandia Investment Management
Boston,
Massachusetts
|
+$1.57M |
| 5 |
CM
Cohanzick Management
Pleasantville,
New York
|
+$741K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
-$23.3M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$22.1M |
| 3 |
SCM
Saba Capital Management
New York
|
-$21M |
| 4 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
-$13.2M |
| 5 |
D.E. Shaw & Co
New York
|
-$12.8M |
ASBP Hedge Fund Activity: Q2 2023 in Review
14 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q2 2023, worth a combined $17M — down 94% from $268M a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of ASBP and 8 opened new positions — a net loss of 43 holders — while 5 trimmed existing stakes and 1 added.
The largest buyer was Arena Investors, opening a new position worth an estimated $1.57M. The largest seller was Glazer Capital LLC, exiting entirely with an estimated $23.3M sold.
- 14 institutional investors held Aspire Biopharma (ASBP) as of Q2 2023, down from 57 in Q1 2023.
- Funds reported $17M of Aspire Biopharma stock for Q2 2023, down 94% quarter-over-quarter.
- 8 funds opened new Aspire Biopharma positions in Q2 2023 and 51 closed out, a net change of -43 holders.
- The largest Aspire Biopharma buyer in Q2 2023 was Arena Investors, an estimated $1.57M added.
- The largest Aspire Biopharma seller in Q2 2023 was Glazer Capital LLC, an estimated $23.3M sold.
Based on aggregated 13F filings for Q2 2023.